Chronic Widespread Pain in HIV: Novel Mechanisms and Therapeutics
Role of Endogenous Opioid Peptides in HIV-associated Chronic Widespread Pain
Florida International University
200 participants
Nov 15, 2021
INTERVENTIONAL
Conditions
Summary
To determine if decreased production or release of endogenous opioid peptides by peripheral immune cells contributes to hypersensitivity in people with HIV
Eligibility
Plain Language Summary
Simplified for easier understanding
This is a simplified summary. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Relistor is a peripherally acting opioid receptor antagonist approved by the FDA for relief of opioid-induced constipation
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04787848